3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
2
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Prostatic Neoplasms
54
Carcinoma, Non-Small-Cell Lung
33
Lung Neoplasms
30
Breast Neoplasms
29
Glioblastoma
23
Multiple Myeloma
21
Glioma
20
Lymphoma
19
Pancreatic Neoplasms
17
Lymphoma, Large B-Cell, Diffuse
17
Carcinoma, Renal Cell
17
Urinary Bladder Neoplasms
16
Brain Neoplasms
14
Sarcoma
13
Squamous Cell Carcinoma of Head and Neck
12
Rectal Neoplasms
11
Neoplasm Metastasis
11
Melanoma
11
Lymphoma, Non-Hodgkin
11
Thyroid Neoplasms
10
Ovarian Neoplasms
10
Oropharyngeal Neoplasms
10
Neuroblastoma
9
Mouth Neoplasms
9
Medulloblastoma
9
Lymphoma, Follicular
9
Ependymoma
9
Colorectal Neoplasms
9
Central Nervous System Neoplasms
9
Astrocytoma
9
Interventions
Gemcitabine
5
Nivolumab
3
Irinotecan
3
Ipilimumab
3
Docetaxel
3
Cyclophosphamide
3
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
3
pegfilgrastim
2
Vincristine
2
Temozolomide
2
Ibandronic Acid
2
Everolimus
2
Doxorubicin
2
CTLA-4 Antigen
2
spartalizumab
1
saracatinib
1
samarium Sm-153 lexidronam
1
pembrolizumab
1
palbociclib
1
liposomal doxorubicin
1
lenvatinib
1
fludarabine
1
anlotinib
1
angiotensin I (1-7)
1
aldesleukin
1
Zoledronic Acid
1
Trabectedin
1
Topotecan
1
Taxes
1
Sunitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Bone Neoplasms
×
Magnetic Resonance Spectroscopy
×
Clear all
NCT01336803
2023-12-27
Osteosarcoma
Stanford University
Phase 2
Completed
32 enrolled
11 charts